Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration by Joseph M. Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou, Thomas P. Hull, Shawn A. Lewis, David G. Miller, Michael A. Novak, Scott D. Pendergast, Hang Pham, Sean M. Platt, Llewelyn J. Rao, Jerome P. Schartman, Lawrence J. Singerman, Richard Donkor, Margaret Fink, Jasmyne McCoy, Helene Karcher

Get full text